Compare ZVRA & MYN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ZVRA | MYN |
|---|---|---|
| Founded | 2006 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance Companies |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 472.9M | 380.8M |
| IPO Year | 2015 | N/A |
| Metric | ZVRA | MYN |
|---|---|---|
| Price | $8.90 | $10.02 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $21.71 | N/A |
| AVG Volume (30 Days) | ★ 540.2K | 196.6K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | ★ 4.12% |
| EPS Growth | ★ 34.27 | N/A |
| EPS | ★ 1.16 | N/A |
| Revenue | ★ $23,612,000.00 | N/A |
| Revenue This Year | $333.64 | N/A |
| Revenue Next Year | $44.19 | N/A |
| P/E Ratio | $7.73 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.19 | $9.13 |
| 52 Week High | $13.16 | $10.26 |
| Indicator | ZVRA | MYN |
|---|---|---|
| Relative Strength Index (RSI) | 53.56 | 44.99 |
| Support Level | $8.61 | $9.90 |
| Resistance Level | $8.99 | $10.21 |
| Average True Range (ATR) | 0.33 | 0.07 |
| MACD | 0.02 | -0.01 |
| Stochastic Oscillator | 65.82 | 20.91 |
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
Blackrock Muniyield NY Quality FD, Inc is a closed-end management investment company. Its objective is to provide shareholders with a high level of current income exempt from federal income taxes. The Fund invests in long-term municipal obligations that are investment grade quality or are considered by the Fund's investment adviser to be of comparable quality, at the time of investment.